Impact of Edoxaban on Thrombin-Dependent Platelet Aggregation

Edoxaban, a direct factor Xa inhibitor (FXa), is the fourth direct oral anticoagulant (DOAC) approved for clinical use. As the main adverse event is bleeding, it is relevant whether edoxaban has additional effects on platelet function. We aimed to assess in vitro aggregation in patients with atrial...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Appl Thromb Hemost
Hauptverfasser: Sokol, Juraj, Nehaj, Frantisek, Ivankova, Jela, Mokan, Michal, Lisa, Lenka, Zolkova, Jana, Vadelova, Lubica, Mokan, Marian, Stasko, Jan
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7573709/
https://ncbi.nlm.nih.gov/pubmed/33054412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620948585
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge